|
Taxol benefit limited to Her2 breast cancer
[they] conducted a clinical study to evaluate the benefits of Taxol in patients with early breast cancer. This study included data from over 1,320 women with breast cancer that had spread to the lymph nodes under the arms (node-positive). All patients had been treated with chemotherapy consisting of Adriamycin® (doxorubicin) plus Cytoxan® (cyclophosphamide). One group of patients was then treated with Taxol, while the other group received no further chemotherapy. - Patients who were HER2-negative and ER-positive derived no benefit from the addition of Taxol.
- Patients who were HER2-positive and either ER-positive or ER-negative had a 40% reduced risk of a cancer recurrence with the use of Taxol.
http://www.ufscc.ufl.edu/Patient/can...rnews&id=40690
Interesting..
__________________
35 y/o
June 06: BC stage I
Grade 3; ER/PR neg
Her-2+++; lumpectomies
Aug 06: Stage IV
liver mets: 6 tumours
July 06 to Jan 07: 2*FEC+6*Taxotere; 3*TACE; LITT
March 07- Sept 07: Vaccination trial (phase 2, peptide based) at the UW (Seattle).
Herceptin since 2006
NED til Oct 09
Recurrence Oct 2009: to internal mammary gland since October 2009 missed on Oct and March 2010 scan.. palpable nodes in May 2010 when I realised..
Nov 2011:7 mets to lungs progressing fast failed hercp/tykerb/xeloda combo..
superior vena cava blocked: stent but face remains puffy
April 2012: Teresa Trial, randomised to TDM1
Nov 2012 progressing on TDM1
Dec 2012 blockage of my airways by tumours, obliteration of these blocking tumours breathing better but hoping for more- at mo too many tumours to count in the lungs and nodes.
Dec 2012 Starting new trial S-222611 phase 1b dual egfr her2+ inhibitor.
'Under no circumstances should you lose hope..' Dalai Lama
|
Threaded Mode